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ABSTRACT
Background: Breast cancer treatments in women with breast
cancer often result in physical impairments that lead to activity
limitations and participation restrictions. These limitations and
restrictions manifest in impaired functional mobility skills that
may impact survivorship. Thus, evaluation of functional mobility is an important part of survivorship care. Purpose: To identify functional mobility outcome measures that possess strong
psychometric properties and are clinically useful for examination
of women treated for breast cancer. Methods: Multiple electronic databases were searched for articles published after 1995.
Studies were included if they reported psychometric properties,
used clinically feasible methods, were performed on adults, and
published in the English language. Each outcome measure was
independently evaluated and rated by two reviewers. A single
Cancer EDGE Task Force Outcome Measure Rating Form was
completed for each category of functional mobility, and a recommendation was made using the 4-point Cancer EDGE Task Force
Rating Scale. Results: Of the original 819 articles found, 211
were included in this review. A total of 11 measures are recommended for clinical use: the Timed Up and Go; the 2-Minute,
6-Minute, and 12-Minute Walk Tests; 10-Meter Walk; 5 Times Sit
to Stand; Short Performance Physical Battery; Physical Battery
for Patients with Cancer; Functional Independence Measure
(FIM); Assessment of Life Habits; and Activity Measure for
Post-acute Care. Conclusions: Many tools are available to assess
upper extremity and overall functional mobility skills in women
Address correspondence to: Mary I. Fisher, PT, PhD, OCS,
CLT, Department of Physical Therapy, University of Dayton,
300 College Park, Dayton, OH 45469 Ph: (937) 229-5617,
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treated for breast cancer. There are currently no tools recommended that assess community participation.
Key Words: breast neoplasms, outcome assessment, patientreported outcomes, psychometrics
INTRODUCTION
Breast cancer is the most common form of cancer in women
in the United States with approximately 12% developing breast
cancer in their lifetime.1 In 2015, an estimated 231,840 new cases
of invasive breast cancer in women will be diagnosed, and in 2011
an estimated 2,889,726 women were living with breast cancer.1
There are approximately 3 million women diagnosed with breast
cancer surviving today.1 For all stages of breast cancer combined,
the 5-, 10-, and 15-year relative survival rates are 89%, 83%,
and 78%, respectively.1 As the number of breast cancer survivors
(BCS) continues to grow, many women will develop significant
impairments of multiple body systems and functions.2
Functional mobility is an essential physical ability categorized within the activities and participation domains of the
International Classification of Functioning, Disability, and Health
(ICF).3 Abilities related to changing and maintaining body position including carrying, moving, and handling objects, and walking and moving, fall under the Mobility domain.3 The Self-Care
domain contains abilities related to washing oneself, toileting,
dressing, eating, and drinking, while the Domestic Life domain
includes acquisition of necessities, household tasks, and caring
for and assisting others.3 The categories of functional measures
evaluated in this review fall under these specific subdomains of
the ICF. Whether a BCS can safely move about, complete selfcare activities, and partake in domestic life must be assessed
as part of the rehabilitation evaluation. Other measures used to
detect and quantify impairments in functional mobility include
additional upper extremity functional tests, tests for activities of
19

daily living, walk tests, and self-report questionnaires identifying
impairments with community participation. Determining which
measures of functional abilities are reliable and valid in this
population provides a means for accurate and thorough assessment of function.
Treatment for breast cancer is generally comprised of
surgery and adjuvant strategies. Surgical interventions include
removal of the tumor and surrounding tissue or mastectomy,
which is the surgical removal of the breast. Treatments may also
involve radiation therapy, chemotherapy that can be administered
before or after surgery, targeted therapy, and/or hormone therapy
such as selective estrogen receptor modifiers, aromatase inhibitors, and ovarian ablation.1 The impact of cancer treatments on
overall function has been explored in the literature, and findings suggest that the cancer experience has a long-term negative
influence on activity and participation abilities of survivors.
Complications from cancer and its treatments may affect some
patients’ functional mobility such as their ability to lift and carry
objects, handle objects, complete self-care activities, and even
walk and move about to carry out these daily activities.4-8 Nearly
25% of cancer survivors report difficulty walking,9 reported
more functional limitations than women without cancer,10 and
generally scored lower on the Short Form-36 (SF-36), a patientreported measure that assesses health-related quality of life.11 In
a study of cancer survivors post-treatment, the majority of whom
were BCS, 22% had difficulty walking and 30% had participation
restrictions.12 The Disabilities of the Arm, Shoulder, and Hand
Questionnaire (DASH), a 30-item patient outcomes assessment
designed to evaluate disorders of the upper limbs and monitor
change or function over time, has been used to capture upper
extremity dysfunction in women with or post breast cancer.13
In survivors 6 months after diagnosis and treatment, 25.6% had
a score greater than 20, where a higher score denotes greater
disability. Scores greater than 20 indicate an impairment of motor
function.13 At a 6-year follow-up, 21.1% had continued dysfunction with scores above 20.14 Certainly, researchers have established that women with limitations in upper extremity range of
motion and strength also report greater difficulties with activities
of daily living (ADLs) and lower overall arm function on selfreported questionnaires.14-16 Declines in activities and participation seen in this population often translate to changes in overall
quality of life.
In 1991, the Task Force on Standards for Measurement in
Physical Therapy (a committee of the American Physical Therapy
Association [APTA]) established the criteria for valid, reliable,
objective, and standardized tests and measures to assist clinicians
in providing the highest quality of care.17 The criteria for appropriate outcome measures needs to consider the following elements:
(1) measurement of a domain within the ICF; (2) purpose of
the measure relevant to obtaining discriminative, predictive, or
evaluative information; (3) disease specific vs. general measure;
self-report vs. performance-based measure; (4) patient’s ability
and goals; (5) psychometric properties, particularly reliability,
validity, diagnostic accuracy, minimal detectable change (MDC),
20

and minimal clinical important difference (MCID); and (6) feasibility, including the time, equipment, cost, space, and training
required to administer and score the test results, overall burden on
the patient to complete the test, and consideration of cultural and
language barriers.18 The use of standardized outcome measures is
an essential component of evidence-based practice and enhances
the communication with patients and payers.19 The main barriers to a standardization of physical therapy outcome measures
include both the length of time and difficulty for patients to
complete the test, as well as the time necessary for clinicians to
administer the test and interpret the results.19
In 2010, the Oncology Section of the APTA created the
Evaluation Database to Guide Effectiveness (EDGE) Task Force
to critically review and recommend outcome measures to be
used when assessing the status of cancer survivors.20 The Breast
Cancer EDGE Task Force subcommittees have provided recommendations for outcome measures in the areas of shoulder and
upper quarter function,21,22 scapular assessment,23 strength and
muscular endurance,24 pain,25 fatigue,26 balance and peripheral
neuropathy,27 health-related quality of life,28 and cardiovascular
fitness.29
This systematic review continues the ongoing efforts of the
EDGE Task Force and evaluates the ways in which functional
mobility is measured clinically in individuals with breast cancer.
These tools provide important information about the patient,
focus intervention strategies, and measure treatment effectiveness, addressing the survivorship needs of women treated for
breast cancer. The reliability, validity, MDC, and/or MCID are
important psychometric properties that need to be established
and assessed to justify the use of the selected outcome measures
in the clinic.18 In addition, tools used to track and measure patient
outcomes should be validated in the population in which they are
used to be most beneficial for the patient. Lastly, these tools need
to be considered in light of clinical utility, including the availability of resources, cost, ease of use, and availability of normative
data. The purpose of this systematic review is to make recommendations of the best methods to evaluate functional mobility in
BCS based on psychometric properties and clinical utility.
METHODS
Search Strategy
The authors systematically investigated the literature for
outcome measures that directly measured functional mobility to
evaluate the psychometric properties and clinical utility for use
assessing BCS. The primary literature search took place during
February and March of 2014 using 8 electronic databases: Google
Scholar, Ovid, PubMed/Medline, CINAHL, Sports Discus, Web
of Science, Cochrane Review, and PEDro. Search terms that were
used included breast cancer or neoplasm in addition to multiple
terms describing functional mobility including function, mobility,
and limb use. The name of established functional tests were also
specifically searched (refer to Appendix 1 for full list of search
terms). Note that this list exceeds the number of functional tests
investigated in this review. The final list includes only those
Rehabilitation Oncology
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measures that were deemed to assess functional mobility skills,
and that had published reports available for analysis. It is possible
that outcome measures were omitted if the search did not reveal
published information on the test.
Study Selection
To be included in this review, studies (1) were published
in English; (2) performed tests of functional mobility; (3)
reported psychometric properties; (4) presented clinically feasible methods; and (5) included adults (≥ 18 years), preferably
women. Included articles were considered if published from
1/1/1995-present. The breast cancer population took first priority
within the search, however, if no studies included this population,
women with other cancers, geriatric patients, and the general
population were considered for review.
Data Extraction
Teams of two reviewers independently performed data
extraction using the Cancer EDGE Task Force Rating Form.20
Tests of functional mobility were categorized into one of 4 groupings: (1) upper extremity functional tests, (2) ADL functional
tests, (3) walk tests, and (4) self-report community participation
tests. The categories for functional mobility were selected based
on the qualities and foci of the functional outcome measures.
Each functional category included a series of tests and assessments. Refer to Appendix 2 for tests listed under each category.
Following data extraction, reviewers independently appraised
each outcome measure using all articles covering the outcome
measure of interest. Outcome measures were rated 1-4 using the
Cancer EDGE Task Force Rating Scale (Figure 1), taking into
consideration both psychometric properties and clinical utility. Outcome measures rated differently by each reviewer were
discussed with 4 primary reviewers until consensus was obtained.
RESULTS
The initial literature search for functional mobility testing in
survivors of breast cancer resulted in 819 articles. The assessors
reviewed all the titles and any duplicates were removed. A total
of 297 articles were retrieved and assessed for eligibility. Abstract
and article titles were then examined to identify studies that
addressed the specific purpose of the research. After exclusions
were applied, 211 articles were reviewed. See Figure 2 for flow
diagram of literature search.

The number of articles reviewed for each category of tests
were: (1) upper extremity functional tests—37, (2) ADL functional tests—23, (3) walk tests—101, and (4) self-report community participation tests—53. Some research studies evaluated
multiple tools; therefore, the number of articles for each category
is not mutually exclusive. Table 1 delineates the clinical usefulness of the recommended tests.
Eleven measures are recommended by the Breast Cancer
EDGE Task Force members for use to measure the functional
mobility skills of BCS in the clinic. These 11 measures are rated
3 or 4 on the Task Force rating scale. Two measures are highly
recommended (4) having been used in research with breast
cancer: the 6-Minute Walk Test (6MWT) and the Timed Up and
Go (TUG). Nine are recommended (3): 2-Minute and 12-Minute
Walk, 10-Meter Walk, 5 Times Sit to Stand, Short Performance
Physical Battery, Physical Battery for Patients with Cancer,
Functional Independence Measure (FIM), Assessment of Life
Habits, and Activity Measure for Post-acute Care. The Task Force
is unable to recommend 10 measures due to lack of psychometric support or poor clinical utility. Two measures scored a 2A:
Barthel Index and Reintegration in to Normal Living; 8 scored
a 2B: Canadian Occupational Performance Measure, Impact on
Participation and Autonomy Questionnaire, Life Satisfaction
Questionnaire, Modified Rankin Scale, Timed 25 Foot Walk,
Arm Mobility Ability Test, Wolf Motor Function Test, Action
Research Arm Test. Finally, 4 measures are not recommended
(1): Functional Status Examination, Participation Objective
Participation Subjective, Participation Survey of Mobility
Limited People, and 6-Minute Arm Test. See Tables 2 (recommended outcome measures) and 3 (not recommended outcome
measures) with Task Force ratings and clinical utility comments.
Detailed psychometric properties of the recommended clinical
measures of functional mobility testing in BCS can be found
in Table 4 (supplemental online table provides detail for all
reviewed outcome measures).
Discussion
The purpose of this review was to systematically identify
and review methods of evaluating functional mobility in BCS
and to make recommendations about these outcome measures
based on psychometric properties and clinical utility. Since
functional mobility comprises activities that enable an individual

4

Highly Recommend

Highly recommended; the outcome has good psychometric properties and good clinical utility. The measure has been used in
research on individuals with or post breast cancer.

3

Recommend

Recommended; the outcome measure has good psychometric properties and good clinical utility. No published evidence that
the measure has been applied to research on individuals with or post breast cancer.

2A

Unable to Recommend
at this time

Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure.
The measure has been used in research on individuals with or post breast cancer.

2B

Unable to Recommend
at this time

Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure. No
published evidence that the measure has been applied to research on individuals with or post breast cancer.

1

Do Not Recommend

Do not recommend; poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.)

Figure 1. Breast Cancer EDGE Task Force rating scale.
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functional mobility of BCS should be included in assessment. It
is for this reason that all levels of functional mobility were evaluated in this review.

Figure 2. Flow of literature search.
to move about in their environment in order to perform ADLs
and participate in life situations,30 the measures reviewed by the
Breast Cancer EDGE Task Force members span upper extremity
functional tests, ADL tests, walk tests, and self-report community
participation questionnaires. Eleven measures are rated 3 (recommend) or 4 (highly recommend).
The ability to complete functional mobility tasks is a necessary part of the rehabilitation experience. Although the upper
limb is the most obvious body part on which to focus, overall

Upper Extremity Functional Tests
Of the upper extremity functional tests included in this
review, only one, the Activity Measure for Post-Acute Care
(AM-PAC), was recommended (rated 3). The AM-PAC assesses
activity limitations based on the ICF model for patients across the
post-acute care setting with varying diagnoses.31 The AM-PAC
measures activity limitations in 3 distinct domains: basic mobility, daily activities, and applied cognitive; and it is available
in two formats: a computer-based version and a short form
version.32 The number of items varies depending on the format,
as well as the setting (eg, in-patient vs. out-patient). The measure
is very thorough and comprehensive, and has undergone substantial psychometric testing and validation, but because the instrument is meant to apply across many settings to as wide a patient
population as possible, the specificity and sensitivity might be
decreased. The AM-PAC was used in studies with other cancer
diagnoses, but not specifically for BCS. There is a fee associated
with use of the instrument and scoring is not intuitive.
Activities of Daily Living Functional Tests
Two measures, the FIM and the Assessment of Life Habits
(LIFE-H), were rated 3 (recommended). The FIM is a widely
used uniform measurement system for evaluating basic quality
of daily living activities in persons with a disability.33 The FIM
is comprised of 18 items (13 motor tasks and 5 cognitive tasks)
and assesses the amount of assistance an individual requires to
complete the activities safely and effectively. Items include skills

Table 1. Clinical Usefulness of Recommended Measures
Measure

Equipment Needed

Cost

Ease of Use

Scoring/
Interpretation

Normative
Data

6-Minute Walk

Yes – Stopwatch

Free

High

Easy

Yes

Timed Up & Go

Yes – Stopwatch, chair,
measuring tape

Free

High

Easy

Yes

5 Times Sit to Stand

Yes – Stopwatch, standard chair

Free

High

Easy

Yes*

2-Minute Walk

Yes – Stopwatch

Free

High

Easy

Yes*

12-Minute Walk

Yes – Stopwatch

Free

High – patient may be
limited by condition

Easy

Yes*

10-Meter Walk

Yes - Stopwatch

Free

Medium – varied procedures

Easy

Yes*

Short Performance
Physical Batter

Yes – Stopwatch, chair,
measuring tape, cones

Free

High

Easy

Yes*

Physical Battery for
Patients with Cancer

No

Free

High - poor reliability for
balance

Difficult

Yes*

Functional Independence
Measure

Yes – varies based on category

Moderate

Low – training required

Moderate

Yes

Assessment of Life
Habits

No

Minimal

High

Difficult

Yes*

Activity Measure for
Post-acute Care

No

Minimal

Medium

Moderate

Yes*

*Not validated in breast cancer populations
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Table 2. Recommended Outcome Measures
Measure

Breast Cancer EDGE
Task Force Rating

Clinical Utility

6-Minute Walk

4

Good clinical utility, free and easy to administer. Evidence with BCS.

Timed Up and Go

4

Good clinical utility, free and easy to administer. Evidence with BCS.

5 times sit to stand

3

Good clinical utility, free and easy to administer, not used in BCS.

2-Minute Walk

3

Good clinical utility, free and easy to administer, not used in BCS.

12-Minute Walk

3

Free to administer but limited clinically with lower functioning individuals.

10-Meter Walk

3

Free and easy to administer, not used in BCS.

Short Performance Physical Battery

3

Free to administer. Not established in BCS.

Physical Battery for Patients with Cancer

3

Specific to the cancer population. May not have time to use in the clinic.

Functional Independence Measure

3

Cost to purchase. 30-40 minutes to complete. Not valid in cancer population.

Assessment of Life Habits

3

Takes time to complete with challenging scoring. Lower clinical utility.

Activity Measure for Post-Acute Care

3

CAT version available. Based on WHO ICF. Not used in BCS.

Abbreviations: BCS, breast cancer survivors; WHO, World Health Organization; ICF, International Classification of Functioning; CAT, computer assisted testing

Table 3. Outcomes Measures Not Recommended
Measure

Breast Cancer EDGE
Task Force Rating

Clinical Utility

Barthel Index

2A

Not used in the cancer population.

Reintegration into Normal Living/Life
Index

2A

10 minutes to complete, insufficient information to recommend at this time.

Canadian Occupational Performance
Measure

2B

Fee to use. No evidence in use in BCS.

Impact on Participation and Autonomy
Questionnaire

2B

30 minutes to complete, not used in cancer population.

Life Satisfaction Questionnaire

2B

10-30 minutes to complete, free, not used in cancer populations.

Modified Rankin Scale

2B

6-30 minutes to complete. Free to complete. Experience raters needed to decrease
bias.

Timed 25 Foot Walk

2B

Easy to administer. Not validated in cancer population.

Arm Mobility Ability Test

2B

Lengthy time to complete and scoring is difficult. No evidence in BCS.

Wolf Motor Function Test

2B

Used in the neurological population but not used in BCS.

Action Research Arm Test

2B

Uses multiple pieces of equipment. Used in the neurological population but not used
in BCS.

Functional Status Exam

1

6-30 minutes to complete. Used in the neurological population.

Participation Objective, Participation
Subjective

1

6-30 minutes to complete. Not recommended, no evidence in cancer populations.

Participation Survey of Mobility Limited
People

1

20-40 minutes to complete online or 60-90 minutes hard copy – lack of clinical
feasibility.

6-Minute Arm Test

1

Used to assess cardiovascular fitness. No psychometric data and difficulty obtaining
the equipment.

Hi-Level Mobility Assessment Tool

1

Developed specifically for high level traumatic brain injury.

Abbreviation: BCS, breast cancer survivor

related to self-care, sphincter control, transfers, locomotion,
communication, and social cognition. The FIM was validated on
a number of populations across a variety of settings with good
psychometric properties.34-36 The FIM is a measure that physical
Rehabilitation Oncology
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therapists are familiar with, and the tool has been used in studies
with a BCS cohort. However, there is a cost associated with use
of the FIM, training/certification is required prior to using the
FIM, and it ideally is scored by consensus with a multi-disci23

Table 4. Psychometric Properties of Recommended Outcome Measures
Measure

Intra-rater
Reliability

Inter-rater
Reliability

Test/Re-test
Reliability

Responsiveness to
Change

Validity

Upper Extremity Functional Tests
Activity Measure
for Post-acute Care
(not tested in cancer
population)

Daily Activity:
ICC = 0.9063
Mobility:
ICC = 0.8663
Applied cognition:
ICC = 0.6863

Daily Activity:
ICC = 0.9663
Mobility:
ICC = 0.9763
Applied cognition:
ICC = 0.9163

MDC
AMPAC Computer version64
basic mobility =4.28 points
Daily activity = 3.7 points
Applied cognitive = 5.55
MDC
AMPAC CAT = 2 points 65

With SF-36: r = .8466
With Gait speed: r = 6566
With 6MWT: r = 0.6766
Internal consistency
Cronbach alpha
Total: 0.92-0.9467
Specific dx groups: 0.90-0.9567

Activities of Daily Living Functional Tests
Functional
Independence
Measure (FIM)
(not tested in cancer
population)

68

ICC = 0.95

ICC = 0.80 0.9069,70

With Barthel Index r = 0.92-0.9471

Assessment of Life
Habits (LIFE-H)
(not tested in cancer
population)

ICC = 0.8972

ICC = 0.74 0.8937,73,74

With Craig Handicap Assessment and
Reporting Technique: r = 0.14 - 0.7675
With Community Integration
Questionnaire: r = 0.54 - 0.7575
Internal Consistency:
Cronbach alpha = 0.82 - 0.9075

ICC = 0.85 0.9778,79,82

ICC = 0.94 - 0.9582

Other populations:
ICC = 0.78 0.9941,85

Walk Tests
2-minute walk test
(not tested in cancer
populations)

6-minute walk test

ICC = 0.83 –
0.98076-80

MDC (older adults):
13.4 - 14 m79,82

With TUG: r = -0.68 - 0.8782,83
With BBS: r = 0.8882
With 6MWT: r = 0.93 – 0.9682,84
With EDSS: r = -0.6184
With MSWS-12: r = -0.7284
With MFIS physical sub-index: r = 0.3184

Cancer population:

Cancer population:

Cancer population:

ICC: 0.93 (0.860.97)40

Coefficient of repeatability:
60m40

With:40

Other populations:
ICC = 0.940.9944,86-92
R = 0.953

Small meaningful change:
20m93

Coefficient of
variation:
r = .04981
Other populations
ICC = 0.74 0.9941,85

SEM estimated ≤ 6.3m83

Substantial meaningful
change:
50m93

12-minute walk test

ICC= 0.7187

ICC = 0.6887

ICC = 0.9841,95

ICC = 0.97 0.9941,95,96

(not tested in cancer
populations)

24

maxi-

perceived physical function r = 0.55
age r = -0.52
Other populations:
With 10MWT: r = -.9592,94
With TUG: r = -0.8890,94,95
With Walking Index for SCI: r = 0.6094
With 2MWT: r = 0.99785
12MWT: r = 0.99485
10m fast gait: r = 0.9490
10m comfortable gait: r = 0.8490

Standardized response mean
(SRM) score = 1.9087

(not tested in cancer
populations)
10-meter walk

exercise capacity r = 0.67
mum workload r = 0.70,

R = 0.75-0.9097
ICC = 0.82 0.9356,66,90,98-100

MDC
.013 - 0.25m/s89,95,101,102

With dependence in self-care:
r = 0.60 - .087102
With dependence in mobility:
r = 0.34- .074102
With dependence in domestic life:
r = 0.34 - 0.74102
With instrumental activities of daily
living: r = 0.76103
With Barthel Index: r = 0.78103
With TUG: ICC = -0.84 to -0.9190
With 6MWT: ICC = 0.89 – 0.9590

Rehabilitation Oncology
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Table 4 Continued.
Measure

Intra-rater
Reliability

Inter-rater
Reliability

Test/Re-test
Reliability

Responsiveness to
Change

Validity

Walk Tests – continued
Timed Up & Go
(Cognitive &
Manual)

5 Times Sit to Stand
(not tested in cancer
populations)

Short Performance
Physical Battery
(SPPB)

ICC=0.9999-101

r = 0.90104

MCID = 1 sec105

Cancer population:
With falls within 1 year: r = 0.85106
With falls within 3 months: r = 0.85106
With falls since cancer diagnosis:
r = 0.74106
With Simmonds Performance Status
Battery: r = 0.85106
Other populations:
With 5 times sit to stand: r = 0.60104
With standing balance: r = -0.31104
With Rapid Disability Rating Scale:
r = 0.42104
With S-36 physical function: r = -0.50104
With 2MWT: r = 0.68 - 0.81107

r= 0.82 – 0.9999-105

MDC 2.5 – 4.2sec101,102,106

With PASE: r = -0.3899
With PDQ-mobility: r = 0.5899
With ABC: r = 0.54 – 0.6899,107
With Mini-BEST: r = 0.7199
With quads MVIC: r = -0.33 – 0.6599,108
With 6MWT: r = 0.60 – 0.7599,108
With 5MWT: r = -0.78100
50 foot walk: r = 0.87100
Repeated trunk flexion: r = 0.64100
With DGI: r = -0.58107

MCID ≥ 2.3 sec107

ICC >0.90118

ICC >0.90118

ICC = 0.82 –
0.92118-121

r = 0.98 and 0.99106

r = 0.69-0.99106

(not tested in cancer
populations)

Physical Performance Battery
for Patients with
Cancer

MDC
1.42 – 2.9 points (elderly)66,93
3.42 points (s/p hip fracture)122

With self-reported mobility = 89%59
With ADL associated disability = 96%59

Cancer pop:
Portions correlated with TUG:106
Walk test: r = 0.85
Sit to stand: r = 0.74
Sock test: r = 0.55
6MWT: r = -0.62
Portions correlated with functional
status:88
ADLs: r = 0.39 – 0.43
Forward reach: r = 0.25
Sit to stand: r = 0.44
6MWT: r = -0.49

Abbreviations: ICC, intraclass correlation coefficient; r, Pearson’s Coefficient Correlation; SEM, standard error of measurement; MDC, minimal detectable change; MCID, minimal clinical
important difference; BCS, breast cancer survivors; QOL, quality of life; 2MWT, 2-minute walk test; 6MWT, 6-minute walk test; BBS, Berg Balance Scale; EDSS, Expanded Disability Status
Scale; MSWS, Multiple Sclerosis Walking Scale; TUG, Timed Up and Go; MFIS, Modified Fatigue Impact Scale; AM-PAC, Activity Measure for Post-acute Care; CAT, Computer Adaptive
Testing; SF-36, Short Form-36

plinary team. The test may take up to 45 minutes to administer/
complete, which can affect its clinical utility.
The LIFE-H assesses the quality of an individual’s social
participation based on one’s perception of difficulty experienced
and how much assistance is required to complete a task.37 The
long and short form of the instrument (ver. 3.0) has 240 and 69
items, respectively, covering 12 domains including nutrition,
personal care, mobility, interpersonal relationships, community
life, and recreation. The LIFE-H is comprehensive and has good
psychometric properties, however, Magasi and colleagues38 point
out that the LIFE-H was not widely used outside of the group
Rehabilitation Oncology
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that developed the instrument, and the conceptual foundation on
which the instrument was grounded was not widely known, limiting its adoption by the clinicians and researchers. The LIFE-H
was not validated in the cancer population. Moreover, scoring
of the instrument is difficult, and it may take an hour or more to
complete the instrument (up to 60 minutes for the short form, up
to 120 minutes for the long form).
Walk Tests
Walk tests fall under the ICF Mobility Domain. The ability
to safely and efficiently walk and move about is considered an
25

essential life skill. The following tests were rated a 3 (recommended) or 4 (highly recommended) by the EDGE Task Force.
The 6MWT and the TUG were rated 4 (highly recommended). Both of these tests exhibit good psychometric properties, and were tested and used extensively with BCS. In the
6MWT, the individual is asked to walk as far as possible for a
total of 6 minutes on a hard, flat surface; the patient is allowed to
self-pace or rest as needed during the test.39 This test was originally developed as a measure of exercise tolerance in patients
with chronic respiratory disease and heart failure, but has since
been used as a performance-based measure of functional capacity
in many other populations.40-44 Among patients with cancer, the
6MWT exhibited good reliability, and the distance walked correlates well to exercise capacity and workload.40 The 6MWT has
been used to assess physical impairments following breast cancer
treatment,45 as well as functional improvements after exercise
programs for BCS.46-48
The second highly recommended test, the TUG, measures the
time in seconds for a person to rise from sitting in a standard chair
with arms, walk 3 meters, turn, walk back to the chair, and sit
down.49 Thus, this test provides an overall assessment of elements
that are important for independent mobility including sit to stand
to sit transfers, ambulation, and turning about in space. The TUG
has good inter/intrarater reliability and is highly correlated with
gait speed,50 which in turn, is a significant predictor of functional
dependency and disability.51,52 Among patients with cancer, the
TUG was used as a measure of performance status, mobility, and
postural control.51,53 Both the 6MWT and the TUG are free and
easy to administer, requiring little to no equipment. The instructions for both tests are also available in many languages.
Six measures in the Walk Test category are rated recommended (rated 3). These tests include the 2-minute and 12-minute
walk, 10-meter walk, as well as physical performance batteries
that incorporated walk tests: Short Performance Physical Battery
(SPPB), and the Physical Performance Battery for Patients with
Cancer. The 5 times sit-to-stand test (FTSST or 5xSST) was
also included in this category. The 2- and 12-minute walk tests
(2MWT, 12MWT) are both variants of the 6MWT. The individuals walk as far as they can in 2 or 12 minutes, respectively. Like
the 6MWT, individuals can rest or stop as needed, and use their
customary walking aid. The 2MWT was proposed as an alternative to the 6MWT as being more clinically feasible for a patient
with significant muscle weakness, gait inefficiency, or fatigue.54
On the other hand, the 12MWT was proposed in response to the
observation that patients tend to walk at a faster pace initially
before settling to a more constant speed, thus a longer walk test
would be a more accurate measure of functional capacity and
exercise tolerance.55 While both of these measures were tested
in other populations and exhibit good clinical utility, the 2MWT
has not been used, to our knowledge, on BCS. The 12MWT may
have limited utility with BCS as the patients who have significant
sequelae from breast cancer treatment (eg, peripheral neuropathy,
cancer-related fatigue, etc) might have difficulty completing the
test due to the longer time frame. The 10-meter walk (10MWT)
26

assesses the time it takes an individual to walk 10 meters. The
distance is then divided by the time to complete that distance in
order to derive gait speed. There are variations of this measure in
which the individual walks at his/her preferred or fastest speed
possible.56 While this test is easy to administer, there are different
reported methods for how to conduct the 10MWT, such as the use
of extra distances to allow the individual to accelerate or decelerate.57 Moreover, there is limited information on its use with BCS.
The SPPB and Physical Performance Battery for Patients
with Cancer are both physical performance batteries. Each of
these batteries attempts to capture a hierarchy of function for a
variety of physical tasks that mimic daily activities. The SPPB
captures mainly lower extremity function, while the Physical
Performance Battery for Patients with Cancer also includes upper
extremity tasks. The SPPB is composed of a balance task, a short
walk at the usual speed, and 5 repetitive chair stands.58 This test
was designed such that it could be performed in almost all clinical and research settings, and to quantify physical performance
changes over time.59 The SPPB captures domains of strength,
endurance, and balance, is relatively easy to administer, and was
used extensively in studies in the older population. However, its
use with BCS is limited, perhaps because lower extremity function is not perceived as an area of immediate concern compared
to upper extremity function. Of note, Curb and colleagues60 report
that the balance subscale of the SPPB has poor reliability, and
suggests using the summary SPPB score or a difference balance
assessment tool if balance is the construct of interest.
The Physical Performance Battery for Patients with Cancer
was devised specifically for the oncology population.61 This
test battery has 9 separate individual tests. While the individual
tests are relatively easy to administer/perform, the total time to
complete the test battery may be up to 40 minutes. The Physical
Performance Battery for Patients with Cancer was used in studies
including BCS, however, the time it takes to complete the test
battery as well as putting the results into context (ie, results of the
battery vs. individual tests) may diminish its clinical usefulness.
The 5xSST assesses lower extremity strength and ability to
perform transitional movements. Individuals are asked to stand up
from a standard chair and sit down 5 times, as quickly as possible,
while keeping arms folded across the chest.62 The 5xSST is quick
and easy to administer and is a test within the SPPB. The 2 Times
Sit to Stand is a test within the Physical Performance Battery for
Patients with Cancer. There are other versions that were reported,
such as a 30-second sit to stand, a 10 times sit to stand, and a
single leg sit to stand. However, the 5xSST and other versions
were not specifically tested in the cancer population.
Self-report Questionnaires/Community Participation
None of the reviewed scales for self-report and community
participation are recommended by this Task Force. They either
lacked psychometric testing or clinical utility presenting issues
for the clinician as the dearth of quality scales leaves a void
in accurate assessment. One might argue that some assessment
is better than no assessment; however, should the assessment
Rehabilitation Oncology
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be unreliable or lack validity, then it may not assess the given
construct accurately. Because the Task Force cannot recommend
any of the measures for self-report and community participation,
using traditional descriptive techniques to define performance is
recommended.

living, walking, and community participation. Eleven measures

CONCLUSION
Assessing functional mobility is an important part of breast
cancer survivorship. Many tools exist that accurately and reliably
assess upper extremity functional mobility, activities of daily

lation is necessary either to develop further existing tools or

are recommended for use by the Oncology EDGE Task Force.
Tools that assess community functional mobility currently lack
either psychometric validation or clinical utility, or both. Further
research exploring community functional mobility for this popudesign new tools that possess both sound psychometric properties
and good clinical utility. Survivorship care for women treated for
breast cancer is enhanced by using the recommended measures.

Appendix 1. Search Terms
Primary search terms: breast cancer, neoplasm, function, functional mobility, limb use
Secondary search terms:
• 5 Times Sit to Stand
• 10 Meter Walk Test
• 2 Minute Walk Test
• 6 Minute Walk Test
• 12 Minute Walk Test
• Action Research Arm Test
• Activity Measure for Post-acute Care
• Arm Motor Ability Test
• Assessment of Life Habits
• Barthel Index
• Canadian Occupational Performance Measure
• Clinical Test of Sensory Interaction and Balance
• Community Balance and Mobility Scale

• Functional Independence Measure
• Functional Reach Test/Modified Functional
Reach Test
• Functional Self-assessment
• Functional Status Examination
• Goal Attainment Scale,
• Hauser Ambulation Index
• High-level Mobility Assessment Tool (HiMAT)
• Impact of Participation and Autonomy
Questionnaire (IPAQ)
• Jebsen Taylor Arm Function Test
• Life Satisfaction Questionnaire (LISAT-9)
• Modified Rankin Scale

•
•
•
•
•
•
•
•
•
•
•
•

Motor Activity Log
Motricity Index
Participation Measure for Post-acute Care
Participation Objective, Participation Subjective
Participation Survey of Mobility Limited People
Physical Performance Battery for Patients with
Cancer
Reintegration to Normal Living/Life Index
Six Minute Arm Test (6-MAT)
Short Performance Physical Battery
Timed 25 Foot Walk
Timed Up & Go (Cognitive and Manual)
Wolf Motor Function Scale

Appendix 2. Categories of Functional Mobility Testing and Respective Tests
Upper Extremity
Functional Movement
Tests
• A
 ction Research Arm Test
• Activity Measure for Post-acute
Care
• A
 rm Motor Ability Test
• Six Minute Arm Test (6-MAT)
• Wolf Motor Function Scale

ADL Functional Tests
Category (Physical and
Self-report)
• A
 ssessment of Life Habits
• A
 ction Research Arm Test
• Activity Measure for Post-acute
Care
• A
 rm Motor Ability Test
• Canadian Occupational
Performance Measure
• Barthel Index
• Functional Independence
Measure/Functional Selfassessment

Walk Tests
•
•
•
•
•
•
•

2 Minute Walk Test
6 Minute Walk Test
12 Minute Walk Test
10 Meter Walk Test
5 Times Sit to Stand
Timed 25 Foot Walk
Timed Up & Go (Cognitive and
Manual)
• High-Level Mobility Assessment
Tool (HiMAT)
• Short Performance Physical Battery
• Physical Performance Battery for
Patients with Cancer

Self-report Community
Participation
• Impact on Participation and Autonomy
Questionnaire (IPAQ)
• Life Satisfaction Questionnaire (LSAT-9)
• Functional Status Examination
• Modified Rankin Scale
• Participation Measure for Post-acute Care
• Participation Objective
• Participation Subjective (POPS)
• Participation Survey of Mobility Limited
People (PSM)
• Reintegration to Normal Living/Life Index

Abbreviation: ADL, activities of daily living
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